LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p

Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved..

Small Nucleolar RNA Host Gene (SNHG16) is a novel cancer-related long noncoding RNA (lncRNA) and functions as an oncogene in a variety of cancers. Nonetheless, the expression patterns, biological function, and potential mechanisms in SNHG16 in pancreatic cancer (PC) remain rarely known. An increase in expression of SNHG16 in PC samples against adjacent normal tissues was shown here. Increased SNHG16 was linked intimately to the tumor-node-metastasis (TNM) stage, distant metastasis, tumor differentiation, and poor overall survival. Loss-of-function experiments revealed that SNHG16 knockdown suppressed the proliferation, formation of colonies, ability to migrate and invade in vitro, along with a lowered growth of the tumor in a mouse model. Mechanistically, SNHG16 might serve as a sponge competitive endogenous RNA (ceRNA) for miR-218-5p, thereby playing a role in regulating the expression of high mobility group box 1 (HMGB1) expression, a known direct miR-218-5p target in PC cells. These results provide novel insight into PC tumorigenesis and suggest that SNHG16 could serve as a likely therapeutic intervention in PC.

Errataetall:

RetractionIn: Biomed Pharmacother. 2024 Feb;171:116188. - PMID 38296726

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:114

Enthalten in:

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 114(2019) vom: 14. Juni, Seite 108862

Sprache:

Englisch

Beteiligte Personen:

Liu, Songyang [VerfasserIn]
Zhang, Wei [VerfasserIn]
Liu, Kai [VerfasserIn]
Liu, Yahui [VerfasserIn]

Links:

Volltext

Themen:

HMGB1 Protein
Invasion
Journal Article
LncRNA
MIRN218 microRNA, human
MiR-218-5p
MicroRNAs
Pancreatic cancer
Proliferation
RNA, Long Noncoding
Retracted Publication
SNHG16
SNHG16 lncRNA, human

Anmerkungen:

Date Completed 29.08.2019

Date Revised 07.02.2024

published: Print-Electronic

RetractionIn: Biomed Pharmacother. 2024 Feb;171:116188. - PMID 38296726

Citation Status MEDLINE

doi:

10.1016/j.biopha.2019.108862

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM296020249